Trials / Recruiting
RecruitingNCT07036965
Comparison of Different Pulsed Field Ablation Catheters in Atrial Fibrillation
Comparison of Different Pulsed Field Ablation Catheters Combined With Stroke Prevention in High Stroke Risk·Atrial Fibrillation: A Prospective, Multicenter, Randomized Controlled Trial
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 292 (estimated)
- Sponsor
- Hangzhou Dinova EP Technology Co., Ltd · Industry
- Sex
- All
- Age
- 118 Years
- Healthy volunteers
- Not accepted
Summary
Pulsed field energy ablation, a non-thermal ablation modality, can potentially reduce post-ablation tissue edema. Previous studies have confirmed the feasibility and safety of combined pulsed field ablation (PFA) and left atrial appendage closure (LAAC) as a one-stop treatment, with few reports of post-ablation tissue edema. However, during PFA procedures, the presence of metallic components in the ablation site (e.g., occluder frames, metallic valves) may lead to arcing during energy delivery, compromising procedural safety. Therefore, when performing PFA+LAAC as a one-stop procedure, a "ablation-first" strategy is recommended. Due to the influence of parameters such as voltage, pulse width, and number of cycles on pulsed field energy characteristics, significant variability in ablation depth and area may exist between different PFA devices. To date, no large-scale clinical studies have compared the efficacy and safety of different PFA systems. Accordingly, this study will conduct a prospective, multicenter, randomized controlled trial to compare the effectiveness and safety of domestic versus imported pulsed field ablation catheters in the treatment of patients with atrial fibrillation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | CardiPulse | abc |
| DEVICE | FaraPulse | bcd |
Timeline
- Start date
- 2025-06-30
- Primary completion
- 2027-07-30
- Completion
- 2031-06-30
- First posted
- 2025-06-25
- Last updated
- 2025-06-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07036965. Inclusion in this directory is not an endorsement.